Rare disease is the most strategically attractive segment in pharmaceuticals by return on investment, regulatory advantage, and pricing power. Orphan drug designation provides seven years of market exclusivity, 50% tax credits on clinical trial costs, accelerated FDA review, and waiver of the Prescription Drug User Fee Act application fee.
Cell and gene therapies are moving from academic medical centers into routine clinical deployment across an expanding list of rare disease indications. Novartis’s Zolgensma for spinal muscular atrophy, and Casgevy — the first CRISPR-based therapy approved for sickle cell disease and beta-thalassemia — have demonstrated that genetic cures are clinically achievable.
This report provides significant competitor information, analysis, and insight critical to the development and implementation of effective marketing and R&D programs.
Topics Covered
• Orphan Drug Strategy
• Gene Therapy In Vivo
• Gene Editing Ex Vivo
• CAR-T in Rare Disease
• Rare Neurological Disease
• Rare Metabolic and Hematological Disease
• Manufacturing and Access
Table of Contents
1. Executive Summary
2. Market Overview
3. Orphan Drug Strategy
4. Gene Therapy In Vivo
5. Gene Editing Ex Vivo
6. CAR-T in Rare Disease
7. Rare Neurological Disease
8. Rare Metabolic and Hematological Disease
9. Manufacturing and Access
10. Competitive Landscape
11. Regional Market Analysis
12. Strategic Conclusions and Recommendations
13. Appendix
List of Tables
Table 1. Market Overview and Leading Products 2025
Table 2. Competitive Landscape by Sub-Segment 2025
Table 3-8. Topic-Specific Analysis Tables
Table 3. Leading Companies — Portfolio and Pipeline Assessment 2025
Table 4. M&A and Licensing Activity 2023-2025
Table 5. Regional Market Analysis
Table 6. Key Risks and Mitigation Strategies
Companies Profiled
Spark Therapeutics
BioMarin
Sarepta
bluebird bio
Ultragenyx
Novartis Gene Therapies
Regenxbio
